CAMBRIDGE, England, March 12, 2013 -- /PRNewswire/ --
ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the UK government-backed Biomedical Catalyst has awarded the company approximately £0.2 million ($0.3 million) to support pre-clinical development of its pneumococcal vaccine, PnuBioVax™, which targets a wide range of strains of the bacteria. This new grant follows the award of approximately £1 million ($1.5 million) at the end of 2012 by the Biomedical Catalyst, to support the development of ImmBio's novel meningococcal B vaccine, MenBioVax™. The Biomedical Catalyst is a programme of public funding managed jointly by the UK's innovation agency, the Technology Strategy Board, and the Medical Research Council, which has to date awarded nearly £96 million to 115 projects to support the accelerated development of innovative solutions to healthcare challenges.
ImmBio's vaccine candidates are based on its proprietary ImmBioVax™ technology platform. This uses novel cell-culture production processes to stress the target bacterial pathogen, mimicking the natural immune response to infection. This innovative approach generates vaccines that incorporate multi-protein complexes, offering potential broad-based protection against a wide range of pathogen strains without the need for adjuvants or other immune stimulators.
"ImmBio is delighted to receive funding from the UK's innovation agency and Medical Research Council to progress the development of our novel vaccines", said Graham Clarke, CEO of ImmBio. "Successfully winning funding in both the first and second Biomedical Catalyst investment rounds represents a major vote of confidence in our ImmBioVax™ vaccine technology. This most recent award recognises the need for effective new vaccines against invasive pneumococcal disease, and the potential of our technology to protect against a wide range of disease-causing strains."
About pneumococcal disease
Invasive pneumococcal disease is caused by Streptococcus pneumoniae bacteria. The infection can be devastating, particuarly in developing countries, and is responsible for greater infant mortality than tuberculosis, HIV and malaria combined. Between 5-10% of adults and 20-40% of children carry the bacteria, and over 90 different strains have been identified to date. These evolve continually leading to the emergence of new strains, and antibiotic resistance is a significant and growing problem. Current vaccines cover only a limited number of existing strains and may not be effective against those that emerge in future. In addition, existing vaccines can be expensive for routine use in developing countries.
ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary novel ImmBioVax™ technology. During vaccine production, ImmBioVax™ mimics the normal immune response to a pathogen. This process produces vaccines containing multi-protein complexes that are designed to elicit broad-based priming of the immune system to block subsequent infection by multiple strains of the pathogen. ImmBio is developing vaccines against a number of diseases, including invasive meningococcal disease, tuberculosis and invasive pneumococcal disease.
About the Biomedical Catalyst
The Biomedical Catalyst, announced by Prime Minister David Cameron in December 2011, is a programme of public funding designed to deliver growth to the UK life sciences sector. Delivered jointly by the Medical Research Council and the Technology Strategy Board, the Biomedical Catalyst provides responsive and effective support for the best life science opportunities arising in the UK. The programme is open to UK academics and SMEs and seeks to support those opportunities that demonstrate the highest scientific and commercial potential, irrespective of medical area. For further information please visit: http://www.innovateuk.org/content/competition/biomedical-catalyst.ashx.
Contacts Graham Clarke CEO ImmBio Tel: +44(0)1223-496117 http://www.immbio.com
Rob Budge RJB Communications Tel: +44(0)1865-760969 Mobile: +44(0)7710-741241